While Eylea and Xarelto continue to drive sales growth at Bayer AG CEO Werner Baumann has highlighted a few future blockbusters on the company's third-quarter media call, including elinzanetant, its promising non-hormonal menopause drug for hot flashes and night sweats.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?